What can be done for patients with cancer of the digestive tract in 1999? Guidelines of the French Foundation of Digestive Tract Cancerology (2(nd) Part);Que faire devant un cancer digestif en 1999? Recommandations de la Fondation Francaise de Cancerologie Digestive (2(e) Partie)

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 5, 1999, Pages 486-496

  Barbare, J C ^a   Bedenne, L ^a   Bouche O ^a   Cadiot, G ^a   Calais, G ^a   De Calan, L ^a   Conroy, T ^a   Ducreux, M ^a   Etienne, P L ^a   Elias, D ^a   Faivre, J ^a   Legoux, J L ^a   Maingon, Ph ^a   Mornex, F ^a   Nordlinger, B ^a   Ollier, J C ^a   Peiffert, D ^a   Pelletier, G ^a   Rat, P ^a   Rougier, P ^a   Ruskone Fourmestraux, A ^a   Seitz, J F ^a   Triboulet, J P ^a   Trinchet, J C ^a   Vetter, D ^a   Ychou, M ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; ORZEL; OXALIPLATIN; RALTITREXED; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; COLON CANCER; DIGESTIVE SYSTEM CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROGNOSIS; RECTUM CANCER; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; FRANCE; HUMANS; LYMPHATIC METASTASIS; LYMPHOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECTAL NEOPLASMS;

EID: 0033033635     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Conférence de Consensus. Conclusions et recommandations du jury. Texte de Consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1998;22:S275-88.
2. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepard L, Zee B, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomized trials (RCTS) (abstract). Proc Am Soc Clin Oncol 1997;16:280a.
3. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma-long term results and evaluation of the indicators of health-related quality of life. Cancer 1998;82:2135-44.
4. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
5. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906.
6. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50.
7. Moertel CG, Fleming TR, Mac Donald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
8. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (5FU) leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089 (abstract). Proc Am Soc Clin Oncol 1998;17:256a.
9. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62.
10. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et ai. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
11. Elias D. Métastases hépatiques synchrones et résécables d'origine colo-rectale : faut-il les réséquer d'emblée ou secondairement ? Hepato-Gastro 1996;3:177-80.
12. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1989;7:1437-46.
13. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993;306:752-5.
14. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The nordic gastrointestinal tumor adjuvant therapy group. Cancer 1994;73:556-62.
15. Beretta G, Bollina R, Cozzi C, Beretta GA, Morbito A. Should we consider the weekly (w), chemotherapy (CT) with fluorouracil (F) + racemic folinic acid (f) a standard treatment for advanced/metastatic carcinoma of digestive tract (DTC) in elderly patients (pts) ? (abstract). Proc Am Soc Clin Oncol 1997;16:259a.
16. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-11.
17. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of non resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996:224:509-20.
18. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
19. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Navarro M, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.
20. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 1995;82:1397-400.
21. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a trench intergroup study. J Clin Oncol 1997;15:808-15.
22. Tournigand C, de Gramont A, Louvet C, André T, Carola E, Gilles Amar V, et al. A simplified bimonthly regiment with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC) (abstract). Proc Am Soc Clin Oncol 1998;17:274a.
23. Scheithauer W, Kornek G, Marczell A, Salem G, Karner J, Kovats E, et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure I-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 1997;15:908-14.
24. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing « Tomudex »(raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex colorectal cancer study group. Ann Oncol 1996;7:961-5.
25. Cocconi G, Cunningham D, Van Cutsem E, François E, Gustavsson B, van Hazel G, et al. Open, randomized, mutticenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 1998;16:2943-52.
26. Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (SFU + LV) in patients with advanced colorectal cancer (ACC) results of a randomized multicenter North American trial (abstract). Proc Am Soc Clin Oncol 1997;16:228a.
27. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) (abstract). Proc Am Soc Clin Oncol 1997;16:229a.
28. de Gramont A, Figer A, Seymour M, Homerin M, Le Bail N, Cassidy J, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) (abstract). Proc Am Soc Clin Oncol 1998;17:257a.
29. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
30. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
31. Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovolin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-17.
32. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-6.
33. Gamelin E, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5FU. Cancer 1996;77:441-51.
34. Gamelin E, Boisdron-Celle M, Delva R, Rebimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-8.
35. Louvet C, Bleiberg H, Gamelin E, François E, André T, Extra JM, et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5 fluorouracil (FU) in FU résistant colorectal cancer (CRC) patients (PTS) is independent of FU + folinic acid (abstract). Proc Am Soc Clin Oncol 1996;15:206a.
36. Elias D, Gachot B, Bonvallot S, Blot F, Sabourin JC, Ducreux M, et al. Carcinose péritonéale traitée par excision complète et immédiate post-opératoire et chimiothérapie intra-péritonéale. Etude de phase II chez 54 patients. Gastroenterol Clin Biol 1997;21:181-7.
37. Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124-9.
38. Ducreux M, Ychou M, Seitz JF, Risse ML, Giovannini M, Bonnay M, et al. Etude de phase I/II avec escalade de dose du CPT11 associé au 5FU + acide folinique (schéma LV5FU2) toutes les 2 semaines dans le traitement du cancer colorectal réfractaire au 5FU (abstract). Gastroenterol Clin Biol 1998;22;157a.
39. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:1 : 251-60.
40. Izzo J, Cvitkovic E, Zarba J, Rougier Ph, Villalobos W, Ducreux M, et al. Low dose 5FU continuous infusion (FUCL) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired intrinsic resistance to 5FU or 5FU folinic (FU-FO) (abstract). Ann Oncol 1992;3:20a.
41. Ducreux M, Rougier Ph, Voni-Hanitrimanga R, Elias D, Fabri MC, Zimmermann P, et al. Chimiothérapie de deuxième ligne des métastases de cancers colorectaux par perfusions continues de 5-fluorouracile (5FU) modulées par l'acide folinique (AF) ou le méthotrexate (MTX). Essai de phase I-II avec étude phannacocinétique.(abstract) Gastroenterol Clin Biol 1996,20:35a.
42. Ducreux M, Coquard R. Traitement adjuvant du cancer du rectum. Gastroenterol Clin Biol 1996;20:858-72.
43. De Calan L, Mosnier H, Gouillat C. Cancer du rectum : bilan et traitement chirurgical curatif. Gastroenterol Clin Biol 1996;20:645-56.
44. Abel ME, Rosen L, Kodner IJ, Fleshman JW, Hicks T, Kennedy HL, et al. Practice parameters for the treatment of rectal carcinoma. Dis Colon Rectum 1993;36:989-1006.
45. Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a scandinavian consensus. Br J Surg 1995;82:1297-9.
46. Heald RJ, Moran BJ, Ryll RD, Sexton R, Mac Farlane JK. Rectal cancer : the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.
47. Fischer B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham L, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-9.
48. Pahlman L, Glimelius B. Pre or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211:187-95.
49. Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-14.
50. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. Cancer 1990;66:49-55.
51. Frykholm GJ, Isacsson U, Nygard K, Montelius A, Jung B, Pahlman L, et al. Preoperative radiotherapy in rectal carcinoma. Aspects of acute adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 1996;35:1039-48.
52. Swedish Rectal Cancer Trial. Initial report from a swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Br J Surg 1993;80:1333-6.
53. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;348:1605-10.
54. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
55. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
56. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
57. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonalds JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
58. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer : initial results of intergroup 0114. J Clin Oncol 1997;15:2030-9.
59. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997;40;5:515-22.
60. Hyams DM, Mamounas EP, Petrelli N, Rickette Hn, Jones J, Wieand HS, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997;40:131-9.
61. Lasser P, Toma C, Pompili P, Ducreux M, Fabri MC, Elias D, et al. Cancer du rectum et métastases synchrones non résécables : intérêt d'une association radiothérapie (RT) + chimiothérapie (CT) + chirurgie (résumé). Gastroenterol Clin Biol 1995;19:53A.
62. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer : results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049-1054.
63. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and a salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-39.
64. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997;15:2040-9.
65. Gérard JP, Romestaing P, Mahe M. Cancer du canal anal : rôle de l'association 5-FU-Cisplatinum. Lyon Chir 1991;87:74-6.
66. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 1987;30:324-33.
67. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, De Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.
68. Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, et al. Cure of helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-5.
69. Ruskone-Fourmestraux A, Aegerter P, Delmer A, Brousse N, Galian A, Rambaud JC. Primary digestive tract lymphoma: a prospective multicentric study of 91 patients. Gastroenterology 1993;105:1662-71.
70. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-21.
71. Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2424-9.
72. Gobbi PG, Dionigi P, Barbieri F, Corbella F, Bertoloni D, Grignani G, et al. The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas. A report of 76 cases and review of the literature. Cancer 1990;65:2528-36.
73. Salles G, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, et al. Agressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the group d'Etude des Lymphomes Agressifs. Am J Med 1991;90:77-94.
74. Bozzetti F, Audisio RA, Giardini R, Gennari L. Role of surgery in patients with primary non-Hodgkin's lymphoma ofthe stomach: an old problem revisited. Br J Surg 1993;80:1101-6.
75. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992;102:1628-38.
76. Tedeschi L. Stages I and II non-Hodgkin's lymphoma of the gastrointestinal tract. Retrospective analysis of 79 patients and review of the literature. J Clin Gastroenterol 1994;2:99-104.
77. Ruskoné-Fourmestraux A, Delmer A, Lavergne A, Molina T, Brousse N, Audouin J, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe d'Etude des Lymphomes Digestifs. Gastroenterology 1997;112:7-16.